OncoMatch/Clinical Trials/NCT06860594
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Is NCT06860594 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Triapine for astrocytoma, idh-mutant, grade 2.
Treatment: Triapine — This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Diffuse Intrinsic Pontine Glioma
Biomarker criteria
Required: IDH1 mutation
Astrocytoma, IDH-mutant
Required: IDH2 mutation
Astrocytoma, IDH-mutant
Required: IDH1 wild-type
GBM or variants, IDH-wildtype
Required: IDH2 wild-type
GBM or variants, IDH-wildtype
Required: H3F3A (H3 K27M) G34 mutation
Diffuse midline gliomas, including pediatric-type H3 G34 mutant tumors
Required: HIST1H3B K27 mutation
Diffuse midline gliomas, including pediatric-type E3 K27 mutant tumors
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — standard dose for gliomas (59.4-60 Gy in 1.8-2 Gy per fraction or equivalent or lower)
Prior history of standard dose radiation for gliomas of 59.4-60 gray (Gy) in 1.8-2 Gy per fraction (or equivalent or lower) is allowed
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/mcL; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100,000/mcL
Kidney function
Creatinine ≤ 1.5 x ULN OR glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m^2
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN); AST/ALT ≤ 3 x institutional ULN
Cardiac function
NYHA class II or better
Absolute neutrophil count ≥ 1,500/mcL. Hemoglobin ≥ 8 g/dL. Platelets ≥ 100,000/mcL. Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN). AST/ALT ≤ 3 x institutional ULN. Creatinine ≤ 1.5 x ULN OR GFR ≥ 50 mL/min/1.73 m^2. NYHA class II or better.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · Irvine, California
- UC San Diego Moores Cancer Center · La Jolla, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify